Lexogen has released a high-throughput SARS-CoV-2 test that it says will allow for mass screening. The test identifies newly infected people even without symptoms.
Lexogen believes that use of the test will help individuals infected with the virus get early treatment and avoid infecting others, according to the firm. It can be used in work environments; samples are self-collected and results are delivered in 24 hours, Lexogen said.Lexogen launches high-throughput SARS-CoV-2 test
Latest in Infectious
WHO approves Abbott mpox test for emergency use
October 4, 2024
Abionic sepsis test gets FDA 510(k) clearance
October 3, 2024